New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - fentanyl 7.65mg (alkaloid powder) - transdermal patch - 75 mcg/h - active: fentanyl 7.65mg (alkaloid powder) excipient: dimeticone polyolefin film (mediflex 1000) 18.75 square centimeters polyester release liner (scotchpak 1022) 28.45 square centimeters no-tox white fgn-4194 nt23 silicone adhesive - mylan fentanyl patch is indicated in the management of chronic cancer pain. mylan fentanyl patch is also indicated in the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. it is indicated for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - fentanyl - transdermal patch - 25 micrograms/hour - fentanyl

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - fentanyl - transdermal patch - 50 micrograms/hour - fentanyl

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - fentanyl - transdermal patch - 100 micrograms/hour - fentanyl

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - fentanyl - transdermal patch - 75 micrograms/hour - fentanyl

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - fentanyl - transdermal patch - 12 micrograms/hour - fentanyl - opioids; phenylpiperidine derivatives - it is indicated in the management of chronic intractable pain in patients requiring opioid analgesia

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 1.28 mg in 1 [usp'u] - fentanyl transdermal system is indicated for management of persistent , moderate to severe chronic pain that: - requires continuous, around-the-clock opioid administration for an extended period of time, and - cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids fentanyl transdermal system should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/hr (see dosage and administration). patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. because serious or life-threatening hypoventilation could result, fentanyl transdermal system is contraindicated for use on an as needed basis (i.e., prn

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 50 ug in 1 h - fentanyl transdermal system is a transdermal formulation of fentanyl indicated for the management of persistent, moderate to severe chronic pain in opioid-tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is required for an extended period of time, and the patient cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids. patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid for a week or longer. fentanyl transdermal system is contraindicated in the following patients and situations due to the risk of fatal respiratory depression: -  in patients who are not opioid‑tolerant [see warnings and precautions (5.2)]. - in the management of acute or intermittent pain, or in patients who require opioid analgesia for a short period of tim

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fentanyl, quantity: 2.55 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 360; polyethylene terephthalate; polyvinylidene flouride; methylated trimethylated silica; heptane; titanium dioxide; strong ammonia solution; industrial methylated spirit; potable water; styrene/acrylates copolymer; trolamine; polyethylene; polytef; dimeticone 350; docusate sodium; propylene glycol; purified water; acrylates copolymer; methoxyisopropyl acetate; 2-ethylhexyl acrylate; ethyl acetate; polyisocyanate; 4,4'-diphenylmethane diisocyanate; silane; polypropylene; ethylene/propylene copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; tris(2,4-ditert-butyphenyl) phosphite; calcium stearate; aluminium magnesium hydroxide carbonate; perflouropropylene/vinylidene diflouride copolymer; 1,3,5-trimethyl-2,4,6-tris(3,5-ditert-butyl-4-hydroxybenzyl)benzene; aluminium calcium sodium silicate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; iron oxide red; pigment yellow 119; zinc stearate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fentanyl, quantity: 10.2 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 360; methylated trimethylated silica; heptane; ethyl acetate; polyisocyanate; 4,4'-diphenylmethane diisocyanate; silane; polyethylene terephthalate; polyethylene; titanium dioxide; polypropylene; ethylene/propylene copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; tris(2,4-ditert-butyphenyl) phosphite; calcium stearate; aluminium magnesium hydroxide carbonate; perflouropropylene/vinylidene diflouride copolymer; 1,3,5-trimethyl-2,4,6-tris(3,5-ditert-butyl-4-hydroxybenzyl)benzene; aluminium calcium sodium silicate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; iron oxide red; pigment yellow 119; zinc stearate; strong ammonia solution; industrial methylated spirit; potable water; styrene/acrylates copolymer; trolamine; polytef; dimeticone 350; docusate sodium; propylene glycol; purified water; acrylates copolymer; methoxyisopropyl acetate; 2-ethylhexyl acrylate; polyvinylidene flouride - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.